BB
MGNX icon

BB Biotech’s MacroGenics MGNX Stock Holding History

BB Biotech’s Portfolio MGNX Stock Details MGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$61.1M Buy
3,400,000
+116,728
+4% +$2.02M 1.54% 22
2018
Q4 		$41.7M Buy
3,283,272
+292,860
+10% +$4.91M 1.34% 23
2018
Q3 		$64.1M Buy
2,990,412
+330,000
+12% +$7.03M 1.7% 20
2018
Q2 		$54.9M Buy
2,660,412
+60,000
+2% +$1.35M 1.59% 18
2018
Q1 		$65.4M Hold
2,600,412
– – 1.81% 17
2017
Q4 		$49.4M Buy
2,600,412
+200,000
+8% +$3.73M 1.39% 17
2017
Q3 		$44.4M Buy
2,400,412
+50,300
+2% +$871K 1.23% 18
2017
Q2 		$41.1M Buy
2,350,112
+90,112
+4% +$1.72M 1.26% 18
2017
Q1 		$42M Buy
2,260,000
+340,000
+18% +$6.56M 1.38% 18
2016
Q4 		$39.2M Buy
1,920,000
+465,000
+32% +$11.7M 1.45% 16
2016
Q3 		$43.5M Buy
1,455,000
+935,000
+180% +$27.8M 1.53% 18
2016
Q2 		$14M Buy
+520,000
New +$11.7M 0.55% 23

Other funds holding MGNX

O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BB Biotech's MGNX Position: Q1 2019 in Review

BB Biotech increased its MacroGenics (MGNX) stake by 3.6% in Q1 2019, buying an estimated $2.02M and bringing the position to 3,400,000 shares worth $61.1M. The position accounts for 1.54% of the portfolio, ranked #22.

BB Biotech first reported a position in MGNX in Q2 2016 and has held it in 12 quarters since. The position peaked at $65.4M in Q1 2018. 157 funds tracked by Wall St. Rank hold MGNX as of Q1 2019.

  • BB Biotech held 3,400,000 shares of MacroGenics worth $61.1M as of Q1 2019.
  • BB Biotech bought 116,728 MacroGenics shares in Q1 2019, an estimated $2.02M.
  • MacroGenics made up 1.54% of BB Biotech's portfolio in Q1 2019, its #22 holding.
  • BB Biotech first reported a position in MacroGenics in Q2 2016 and has held it in 12 quarters since.
  • BB Biotech's MacroGenics position peaked at $65.4M in Q1 2018.
  • 157 funds tracked by Wall St. Rank held MacroGenics as of Q1 2019.

Based on BB Biotech's 13F filing for Q1 2019, filed 13 May 2019.